Users of OTC derivatives are not prepared for regulatory onslaught

risk management

Regulatory requirements expected in the US and Europe will be difficult for buy-side companies to implement. Counterparty credit risk and collateral management for OTC derivatives will be challenging.

The analysis* by BNY Mellon shows what the buy-side needs to do now as well as when expected industry regulatory changes are made. The study focused on the standardisation of over the counter (OTC) derivatives and a migration to central clearing.

Until now industry best practice in this area has cen

To continue reading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an indvidual account here: